Kura Oncology (KURA) Capital Expenditures (2014 - 2026)

Kura Oncology (KURA) has 13 years of Capital Expenditures data on file, last reported at $128000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 56.16% year-over-year to $128000.0 in Q1 2026; TTM through Mar 2026 was $6.5 million, a 852.06% increase from a year earlier, with the FY2025 full-year figure at $6.6 million, up 1306.36% from the prior year.
• Capital Expenditures for Q1 2026 stood at $128000.0, down from $2.3 million in the prior quarter.
• Over the last five years, Capital Expenditures for KURA reached as high as $2.6 million in Q3 2025 and fell as low as $12000.0 in Q4 2022.
• Historically, Capital Expenditures has averaged $502000.0 across 5 years, with a median of $112000.0 in 2023.
• Across the five-year window, Capital Expenditures slumped 97.01% in 2022 and jumped 9012.5% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $12000.0 in 2022, then soared by 33.33% to $16000.0 in 2023, then jumped by 2225.0% to $372000.0 in 2024, then soared by 523.92% to $2.3 million in 2025, then sank by 94.49% to $128000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $128000.0 in Q1 2026, $2.3 million in Q4 2025, and $2.6 million in Q3 2025.